阿片类药物维持治疗作为纽约市阿片类药物依赖者的减少伤害工具：有必要扩大在边缘化人群中使用丁丙诺啡/纳洛酮的机会。
Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.
机构信息
Harm Reduction Coalition, New York, New York 10025, USA.
出版信息
J Addict Dis. 2012;31(3):278-87. doi: 10.1080/10550887.2012.694603.
Abstract
The aim of this pilot study was to assess the effectiveness of buprenorphine/naloxone (BUP/NX) among marginalized, opioid-dependent individuals in terms of retention in and cycling into and out of a harm-reduction program. This pilot study enrolled 100 participants and followed them from November 2005 to July 2008. The overall proportion of patients retained in the program at the end of 3, 6, 9, and 12 months was 68%, 63%, 56%, and 42%, respectively. This pilot study demonstrated that BUP/NX could be successfully used to treat marginalized heroin users.
摘要
本研究旨在评估丁丙诺啡/纳洛酮（BUP/NX）对边缘化的阿片类药物依赖者在进入和退出减少伤害项目方面的保留和循环效果。本研究共纳入 100 名参与者，从 2005 年 11 月至 2008 年 7 月进行随访。分别在 3、6、9 和 12 个月时，保留在方案中的患者比例分别为 68%、63%、56%和 42%。本研究表明，BUP/NX 可成功用于治疗边缘化的海洛因使用者。
相似文献
1
Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.
J Addict Dis. 2012;31(3):278-87. doi: 10.1080/10550887.2012.694603.
2
Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
Addict Sci Clin Pract. 2019 May 6;14(1):20. doi: 10.1186/s13722-019-0149-1.
3
Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
J Gen Intern Med. 2012 Jun;27(6):669-76. doi: 10.1007/s11606-011-1962-8. Epub 2012 Jan 4.
4
Suboxone misuse along the opiate maintenance treatment pathway.
J Addict Dis. 2013;32(1):53-67. doi: 10.1080/10550887.2012.759860.
5
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1(Suppl 1):S22-32. doi: 10.1097/QAI.0b013e318209751e.
6
A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
Addiction. 2012 Jan;107(1):142-51. doi: 10.1111/j.1360-0443.2011.03577.x. Epub 2011 Oct 12.
7
A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
J Addict Med. 2014 May-Jun;8(3):176-82. doi: 10.1097/ADM.0000000000000035.
8
Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1(Suppl 1):S83-90. doi: 10.1097/QAI.0b013e31820bc9a5.
9
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9.
10
Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
J Addict Dis. 2016 Oct-Dec;35(4):325-338. doi: 10.1080/10550887.2016.1195608. Epub 2016 Jun 7.
引用本文的文献
1
Rates of Receiving Medication for Opioid Use Disorder and Opioid Overdose Deaths During the Early Synthetic Opioid Crisis: A County-level Analysis.
Epidemiology. 2025 Mar 1;36(2):186-195. doi: 10.1097/EDE.0000000000001816. Epub 2023 Nov 22.
2
"I still can feel the sickness": Withdrawal experiences of people on methadone maintenance treatment.
J Subst Use Addict Treat. 2025 Mar;170:209616. doi: 10.1016/j.josat.2024.209616. Epub 2024 Dec 23.
3
Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
Harm Reduct J. 2024 Mar 26;21(1):69. doi: 10.1186/s12954-024-00983-2.
4
Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
Addict Sci Clin Pract. 2023 Jun 10;18(1):40. doi: 10.1186/s13722-023-00394-x.
5
Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago.
J Subst Use Addict Treat. 2023 Jul;150:209054. doi: 10.1016/j.josat.2023.209054. Epub 2023 Apr 23.
6
Descriptive study: the novel "full spectrum people-with-opioid-use-disorder care model".
Harm Reduct J. 2023 Apr 12;20(1):47. doi: 10.1186/s12954-023-00778-x.
7
Awareness, perception and utilization of a mobile health clinic by people who use drugs.
Ann Med. 2022 Dec;54(1):138-149. doi: 10.1080/07853890.2021.2022188.
8
Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
Harm Reduct J. 2022 Dec 3;19(1):132. doi: 10.1186/s12954-022-00718-1.
9
Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.
Addict Sci Clin Pract. 2022 Nov 5;17(1):60. doi: 10.1186/s13722-022-00342-1.
10
The Role of Context in Integrating Buprenorphine into a Drop-In Center in Kampala, Uganda, Using the Consolidated Framework for Implementation Research.
Int J Environ Res Public Health. 2022 Aug 20;19(16):10382. doi: 10.3390/ijerph191610382.
本文引用的文献
1
The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
Drug Alcohol Depend. 2012 Jun 1;123(1-3):72-8. doi: 10.1016/j.drugalcdep.2011.10.016. Epub 2011 Nov 16.
2
Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
J Addict Med. 2011 Dec;5(4):254-63. doi: 10.1097/ADM.0b013e3182312983.
3
Impact of in-patient research participation on subsequent heroin use patterns: implications for ethics and public health.
Addiction. 2012 Mar;107(3):642-9. doi: 10.1111/j.1360-0443.2011.03664.x.
4
Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program.
J Psychoactive Drugs. 2011 Apr-Jun;43(2):136-45. doi: 10.1080/02791072.2011.587704.
5
Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.
J Addict Med. 2011 Sep;5(3):175-80. doi: 10.1097/ADM.0b013e3182034e31.
6
Buprenorphine in the treatment of opiate dependence.
J Psychoactive Drugs. 2010 Jun;42(2):161-75. doi: 10.1080/02791072.2010.10400689.
7
Post-marketing surveillance of methadone and buprenorphine in the United States.
Pain Med. 2010 Jul;11(7):1078-91. doi: 10.1111/j.1526-4637.2010.00877.x. Epub 2010 Jun 8.
8
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
Addiction. 2010 Apr;105(4):709-18. doi: 10.1111/j.1360-0443.2009.02843.x.
9
Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.
Am J Addict. 2009 Sep-Oct;18(5):346-55. doi: 10.3109/10550490903077820.
10
Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
Clin Infect Dis. 2009 Nov 1;49(9):1433-40. doi: 10.1086/630209.
Zotero 插件